Lilly Shares Slip on Weak Early Data From its Obesity Pill
Wall Street Journal
Last updated: April 25, 2026
Eli Lilly's new weight loss pill, Foundayo, appears to be experiencing a slow market entry, as indicated by early prescription volume data. This has led to a nearly 4% drop in the company's share price on Friday.
- Eli Lilly commenced the sale of its new weight loss medication, Foundayo, in early April.
- Preliminary data concerning the prescription volume for Foundayo suggests a subdued initial uptake since its launch.
- The company's stock experienced a notable decline of almost 4% following the release of this information.
- This early data suggests that the pill, aimed at the growing obesity market, may not be meeting initial sales expectations.
- Further prescription data will be crucial in determining the long-term success and market penetration of Foundayo.
- The performance of Foundayo is significant for Eli Lilly, given the substantial market potential for effective weight loss treatments.
- The reaction in the stock market indicates investor concern over the initial sales trajectory of this new pharmaceutical product.
